Key Events This Week
11 May: Stock opens at Rs.93.98, marginally down amid broad market weakness
12 May: Sharp 2.55% decline to Rs.91.58 as Sensex falls 2.19%
13 May: Partial recovery with 1.56% gain to Rs.93.01, Sensex up 0.32%
14 May: Slight dip to Rs.92.64 despite Sensex rising 1.01%
15 May: Heavy sell-off on quarterly results, stock plunges 5.78% to Rs.87.29
11 May: Stock Opens Lower Amid Broad Market Sell-Off
Par Drugs & Chemicals Ltd began the week at Rs.93.98, down 0.11% from the previous Friday’s close of Rs.94.08. This modest decline occurred alongside a significant Sensex drop of 1.40% to 35,679.54, reflecting a broadly negative market sentiment. The stock’s relative resilience on this day suggested initial investor caution but no immediate reaction to company-specific news.
12 May: Accelerated Decline Mirrors Market Weakness
The stock fell sharply by 2.55% to Rs.91.58, underperforming the Sensex’s 2.19% decline to 34,899.09. This day’s volume remained moderate at 4,948 shares, indicating steady selling pressure. The drop aligned with growing concerns about the company’s financial health, which would be confirmed later in the week.
13 May: Partial Recovery Despite Market Stability
Par Drugs & Chemicals rebounded 1.56% to Rs.93.01, while the Sensex gained 0.32% to 35,010.26. The recovery was on relatively lower volume of 3,989 shares, suggesting cautious buying interest. This uptick may have reflected short-term technical support or anticipation ahead of the quarterly results announcement.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
14 May: Slight Decline Despite Sensex Gains
The stock edged down 0.40% to Rs.92.64 on low volume of 3,805 shares, contrasting with a 1.01% Sensex gain to 35,364.44. This divergence suggested emerging company-specific concerns ahead of the quarterly earnings release. The muted price action indicated investor hesitation amid mixed signals.
15 May: Sharp 5.78% Drop Following Quarterly Results
Par Drugs & Chemicals plunged 5.78% to Rs.87.29 on heavy volume of 23,702 shares, reacting negatively to the company’s quarterly financial disclosure. The Sensex also declined 0.36% to 35,236.50, but the stock’s fall was more pronounced, reflecting investor disappointment with the results.
The quarterly report revealed net sales of ₹19.61 crores, the lowest in recent quarters, and a PBDIT of ₹1.44 crores, signalling margin pressures with an operating profit margin of 7.34%. Profit before tax excluding other income dropped sharply to ₹0.47 crores, while earnings per share fell to ₹0.69, the lowest in recent periods. The profit after tax for the quarter was ₹0.85 crores, down 75.6% compared to the previous four-quarter average.
Despite a robust six-month PAT growth of 153.36% to ₹5.65 crores, the sharp quarterly decline raised concerns about the company’s near-term financial stability. The mojo grade was downgraded to Sell on 27 April 2026, reflecting the negative trend shift from a positive score of 7 to -10 over three months.
Why settle for Par Drugs & Chemicals Ltd? SwitchER evaluates this micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Weekly Price Performance: Par Drugs & Chemicals vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-05-11 | Rs.93.98 | -0.11% | 35,679.54 | -1.40% |
| 2026-05-12 | Rs.91.58 | -2.55% | 34,899.09 | -2.19% |
| 2026-05-13 | Rs.93.01 | +1.56% | 35,010.26 | +0.32% |
| 2026-05-14 | Rs.92.64 | -0.40% | 35,364.44 | +1.01% |
| 2026-05-15 | Rs.87.29 | -5.78% | 35,236.50 | -0.36% |
Key Takeaways from the Week
Negative Quarterly Financials: The sharp decline in net sales to ₹19.61 crores and operating profit margin contraction to 7.34% highlight operational challenges. The 75.6% drop in quarterly PAT compared to the previous four-quarter average is a significant red flag.
Mixed Profit Trends: While the latest quarter was weak, the six-month PAT growth of 153.36% to ₹5.65 crores indicates some recovery in the preceding quarter, suggesting volatility in earnings performance.
Market Reaction and Downgrade: The downgrade to a mojo grade of Sell and the stock’s 7.22% weekly decline versus the Sensex’s 2.63% fall reflect investor concerns about sustainability of earnings and operational momentum.
Volume Spike on Results Day: The heavy volume of 23,702 shares on 15 May indicates strong selling pressure following the disappointing results, signalling a shift in market sentiment.
Long-Term Underperformance: The stock’s year-to-date decline of 13.37% contrasts with an 8.84% gain in the Sensex, and the three-year return disparity is even more pronounced, underscoring ongoing challenges relative to the broader market.
Conclusion: A Challenging Week for Par Drugs & Chemicals Ltd
Par Drugs & Chemicals Ltd experienced a difficult week marked by a significant decline in quarterly financial performance and a corresponding sharp drop in its stock price. The company’s contraction in sales, margins, and earnings per share, coupled with a downgrade to a Sell mojo grade, has heightened investor caution. Despite some positive six-month profit trends, the immediate quarter’s results raise questions about near-term stability and operational efficiency.
The stock’s underperformance relative to the Sensex and the spike in selling volume on results day reflect a market reassessment of the company’s prospects. Given its micro-cap status and sector pressures, continued monitoring of upcoming financial disclosures and management commentary will be essential to understand whether this downturn is temporary or indicative of deeper structural issues.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
